Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches

Daniela Femia, Natalie Prinzi, Andrea Anichini, Roberta Mortarini, Federico Nichetti, Francesca Corti, Martina Torchio, Giorgia Peverelli, Filippo Pagani, Andrea Maurichi, Ilaria Mattavelli, Massimo Milione, Nice Bedini, Ambra Corti, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu

Research output: Contribution to journalArticle

Abstract

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors. More recently, immunotherapy agents such as avelumab, pembrolizumab, and nivolumab, which act by blocking the programmed cell-death (PD)-1/PD-L1 immune checkpoint, have shown promising results, especially in the advanced setting, and should now be considered standard of care for metastatic MCC. Current research is focusing on developing new immunotherapeutic strategies, identifying predictive biomarker to aid in the selection of patients responsive to immunotherapy, and defining combination approaches to increase efficacy in refractory patients.

Original languageEnglish
Pages (from-to)567-582
Number of pages16
JournalTargeted Oncology
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Merkel Cell Carcinoma
Immunotherapy
Cell Death
Radiotherapy
Drug Therapy
Sentinel Lymph Node Biopsy
Somatostatin Receptors
Peptide Receptors
Neuroendocrine Tumors
Poly(ADP-ribose) Polymerases
Angiogenesis Inducing Agents
Standard of Care
Phosphatidylinositol 3-Kinases
Patient Selection
Therapeutics
Biomarkers
Genome
Apoptosis
Neoplasm Metastasis
Recurrence

Cite this

Treatment of Advanced Merkel Cell Carcinoma : Current Therapeutic Options and Novel Immunotherapy Approaches. / Femia, Daniela; Prinzi, Natalie; Anichini, Andrea; Mortarini, Roberta; Nichetti, Federico; Corti, Francesca; Torchio, Martina; Peverelli, Giorgia; Pagani, Filippo; Maurichi, Andrea; Mattavelli, Ilaria; Milione, Massimo; Bedini, Nice; Corti, Ambra; Di Bartolomeo, Maria; de Braud, Filippo; Pusceddu, Sara.

In: Targeted Oncology, Vol. 13, No. 5, 10.2018, p. 567-582.

Research output: Contribution to journalArticle

Femia, Daniela ; Prinzi, Natalie ; Anichini, Andrea ; Mortarini, Roberta ; Nichetti, Federico ; Corti, Francesca ; Torchio, Martina ; Peverelli, Giorgia ; Pagani, Filippo ; Maurichi, Andrea ; Mattavelli, Ilaria ; Milione, Massimo ; Bedini, Nice ; Corti, Ambra ; Di Bartolomeo, Maria ; de Braud, Filippo ; Pusceddu, Sara. / Treatment of Advanced Merkel Cell Carcinoma : Current Therapeutic Options and Novel Immunotherapy Approaches. In: Targeted Oncology. 2018 ; Vol. 13, No. 5. pp. 567-582.
@article{d81ddb84a5174ffba155cdea77b4cb1c,
title = "Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches",
abstract = "Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors. More recently, immunotherapy agents such as avelumab, pembrolizumab, and nivolumab, which act by blocking the programmed cell-death (PD)-1/PD-L1 immune checkpoint, have shown promising results, especially in the advanced setting, and should now be considered standard of care for metastatic MCC. Current research is focusing on developing new immunotherapeutic strategies, identifying predictive biomarker to aid in the selection of patients responsive to immunotherapy, and defining combination approaches to increase efficacy in refractory patients.",
author = "Daniela Femia and Natalie Prinzi and Andrea Anichini and Roberta Mortarini and Federico Nichetti and Francesca Corti and Martina Torchio and Giorgia Peverelli and Filippo Pagani and Andrea Maurichi and Ilaria Mattavelli and Massimo Milione and Nice Bedini and Ambra Corti and {Di Bartolomeo}, Maria and {de Braud}, Filippo and Sara Pusceddu",
year = "2018",
month = "10",
doi = "10.1007/s11523-018-0585-y",
language = "English",
volume = "13",
pages = "567--582",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "5",

}

TY - JOUR

T1 - Treatment of Advanced Merkel Cell Carcinoma

T2 - Current Therapeutic Options and Novel Immunotherapy Approaches

AU - Femia, Daniela

AU - Prinzi, Natalie

AU - Anichini, Andrea

AU - Mortarini, Roberta

AU - Nichetti, Federico

AU - Corti, Francesca

AU - Torchio, Martina

AU - Peverelli, Giorgia

AU - Pagani, Filippo

AU - Maurichi, Andrea

AU - Mattavelli, Ilaria

AU - Milione, Massimo

AU - Bedini, Nice

AU - Corti, Ambra

AU - Di Bartolomeo, Maria

AU - de Braud, Filippo

AU - Pusceddu, Sara

PY - 2018/10

Y1 - 2018/10

N2 - Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors. More recently, immunotherapy agents such as avelumab, pembrolizumab, and nivolumab, which act by blocking the programmed cell-death (PD)-1/PD-L1 immune checkpoint, have shown promising results, especially in the advanced setting, and should now be considered standard of care for metastatic MCC. Current research is focusing on developing new immunotherapeutic strategies, identifying predictive biomarker to aid in the selection of patients responsive to immunotherapy, and defining combination approaches to increase efficacy in refractory patients.

AB - Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors. More recently, immunotherapy agents such as avelumab, pembrolizumab, and nivolumab, which act by blocking the programmed cell-death (PD)-1/PD-L1 immune checkpoint, have shown promising results, especially in the advanced setting, and should now be considered standard of care for metastatic MCC. Current research is focusing on developing new immunotherapeutic strategies, identifying predictive biomarker to aid in the selection of patients responsive to immunotherapy, and defining combination approaches to increase efficacy in refractory patients.

U2 - 10.1007/s11523-018-0585-y

DO - 10.1007/s11523-018-0585-y

M3 - Article

C2 - 30073632

VL - 13

SP - 567

EP - 582

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 5

ER -